» Articles » PMID: 18573672

Efficacy and Tolerability of Nevirapine- Versus Efavirenz-containing Regimens in HIV-infected Thai Children

Overview
Publisher Elsevier
Date 2008 Jun 25
PMID 18573672
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based highly active antiretroviral therapy (HAART) has been the most affordable regimen for the HIV-infected in developing countries. There are limited data comparing nevirapine (NVP) to efavirenz (EFV) in HIV-infected children. This study aimed to assess the efficacy and tolerability of NVP-based regimens compared to EFV-based regimens in HIV-infected children in Thailand.

Methods: The medical records of HIV-infected children who had received NNRTI-based regimens for more than 6 months at the Department of Pediatrics, Siriraj Hospital, Mahidol University, Thailand, were reviewed.

Results: Of the 139 HIV-infected children studied, 70 were male, and the median age at treatment initiation was 6.08 years (range 0.32-14.56 years); the median duration of follow-up was 36 months (range 6-66 months). The median baseline CD4 cell count was 185cells/mm(3) (range 2-3482cells/mm(3)) and the median baseline CD4 percentage was 7.20% (range 0.11-36.57%). An NVP-based regimen was initiated in 61 (44%): 38 antiretroviral (ARV)-naïve and 23 ARV-experienced. An EFV-based regimen was initiated in 78 (56%): 34 ARV-naïve and 44 ARV-experienced. The CD4 cell count and percentage gains were not different between the NVP and EFV groups in both the ARV-naïve and the ARV-experienced. However, ARV-naïve children who received an EFV regimen had significantly lower baseline CD4 levels than those who received an NVP regimen. ARV-naïve children had a better CD4 response than the ARV-experienced. The survival rates of children in the NVP groups were not different from those in the EFV groups for both the ARV-naïve and the ARV-experienced. Treatment failure occurred in one ARV-naïve NVP case (2.6%), two ARV-naïve EFV cases (5.8%), and nine ARV-experienced NVP cases (39%) at 24 months of treatment, and 11 ARV-experienced EFV cases (25%) at 18 months of treatment. Seven (10%) children had adverse effects from treatment with NVP. The main side effects were rash and hepatitis; six had to switch to EFV. Four (5%) children had adverse effects from treatment with EFV; two had to switch to NVP.

Conclusions: Both NVP- and EFV-based HAART regimens were effective in children in Thailand for at least 3 years. HIV-infected Thai children generally tolerated NNRTI well.

Citing Articles

Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine Zidovudine-Lamivudine-Efavirenz Antiretroviral Treatment (ART) Among HIV-1 Infected Children: Asella Teaching and Referral Hospital, South-East Ethiopia.

Sorsa A Open Med Inform J. 2018; 12:11-18.

PMID: 29875890 PMC: 5958299. DOI: 10.2174/1874431101812010011.


Hepatic, Renal, Hematologic, and Inflammatory Markers in HIV-Infected Children on Long-term Suppressive Antiretroviral Therapy.

Melvin A, Warshaw M, Compagnucci A, Saidi Y, Harrison L, Turkova A J Pediatric Infect Dis Soc. 2017; 6(3):e109-e115.

PMID: 28903520 PMC: 5907869. DOI: 10.1093/jpids/pix050.


Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.

Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C AIDS. 2017; 31(7):905-915.

PMID: 28060017 PMC: 5572624. DOI: 10.1097/QAD.0000000000001376.


Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw L, Mursleen S, Irlam J, Spaulding A, Rutherford G, Siegfried N Cochrane Database Syst Rev. 2016; 12:CD004246.

PMID: 27943261 PMC: 5450880. DOI: 10.1002/14651858.CD004246.pub4.


Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective study.

Mutwa P, Boer K, Asiimwe-Kateera B, Tuyishimire D, Muganga N, Lange J PLoS One. 2014; 9(11):e111948.

PMID: 25365302 PMC: 4218827. DOI: 10.1371/journal.pone.0111948.